A Comparison of Bupropion SR and Placebo for Smoking Cessation
Status:
Completed
Trial end date:
2005-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to examine whether the adjunctive use of bupropion SR in the
context of a psychoeducational program modified for people with schizophrenia might improve
the likelihood of successful abstinence in this population. If bupropion SR is effective for
reducing cigarette smoking, then it will be important to determine if decreased nicotine
intake is associated with a worsening of psychotic, anxiety or depressive symptoms. In
addition, it would be important to determine the effect that a reduction in nicotine
stimulation would have on patient's cognitive functioning, as nicotinic receptors have been
shown to regulate attention and memory function, and it is hypothesized that these functions
are normalized by acute nicotine administration in people with schizophrenia
Phase:
Phase 4
Details
Lead Sponsor:
University of Maryland University of Maryland, Baltimore
Collaborators:
US Department of Veterans Affairs VA Office of Research and Development